Trial document

drksid header


Trial Description

start of 1:1-Block title


Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-PROGRESS)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The pandemic triggered by the new virus SARS-CoV-2 presents the German and international health systems with previously unknown challenges. There are currently no effective specific therapies for the treatment of the lung disease COVID-19 caused by this virus. The effects of infection with SARS-CoV-2 range from symptomless to typical upper respiratory tract infections, which may result in pneumonia, which in turn may result in failure of the lungs and other organs, associated with high mortality.
The aim of the joint project PROVID is to contribute to better outcome prediction for COVID-19 patients, to better clinical management, and to the development of new therapies. To this end, we will collect detailed data of on the course of COVID-19 patients and deeply characterize them at the molecular level. We also aim to identify compounds with the potential to improve outcome.
Patient recruitment for the PROVID study is supported by three well-established clinical research platforms: CAPNETZ (competence network CAP, since 2002, world's largest database and biobank for CAP), PROGRESS (Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis, since 2007) and CAPSyS (Systems Medicine of Community-Acquired Pneumonia, since 2014). Through these platforms, patients will be recruited into three separate patient cohorts (PROVID-CAPNETZ, PROVID-PROGRESS, PROVID-CAPSyS). Data and biomaterials will be jointly analyzed to reach the envisaged aims.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Infections with the novel Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2) manifest with a broad spectrum of clinical presentations ranging from asymptomatic infections, upper respiratory tract infections with mild symptoms, and uncomplicated pneumonia to severe pneumonia with lung failure and high mortality. With more close to 40 million documented infections and more than one million deaths (as of October 19, 2020, Johns Hopkins CSSE), there still is a great need to improve the development of therapies and the clinical treatment of COVID-19. We would like to contribute to respective international efforts. Based on current data, COVID-19 associated lower respiratory tract infections and lung damage are not directly comparable to any known types of pneumonia, including viral infections such as influenza or MERS-CoV. Therefore, specific instructions, such as guidelines defined for other forms of pneumonia (CAP), likely have to be adapted for COVID-19.
With COVID-19, severe lung damage can be associated with relative well-being. In the course of disease (several days), sudden lung failure may occur. While the lung initially shows a relatively high compliance after intubation, lung function deteriorates rapidly to severe ARDS in most patients. After intubation, patients require mechanical ventilation over a relatively long period of time (17 days on average).
To improve the clinical management of COVID-19 and its complications, there is an urgent need for clinical (e.g., scores) and molecular (e.g., biomarkers) predictors of COVID-19 progression and for new therapeutic targets. Advanced age and comorbidities have been identified as risk factors for fatal disease progression. A recent multivariate analysis confirmed that higher age, a higher Sequential Organ Failure Assessment (SOFA) score and a D-dimer concentration > 1 μg/l at hospitalization are associated with higher mortality. However, a severe course of COVID-19 is not excluded in younger and seemingly healthy patients. The course of COVID-19 currently remains unpredictable. Since SARS-CoV-2 is a new virus, host- and virus-dependent mechanisms associated with the clinical appearance of COVID-19 are not yet well understood. Therefore, PROVID aims to identify clinical and molecular predictors of COVID-19 progression and therapeutic targets to improve the clinical management of COVID-19 patients. Specific objectives are:
1) Analysis of established clinical pneumonia and sepsis scores and biomarkers/molecular signatures to predict COVID-19 disease progression,
2) Identification of host factors (RNA, proteins, antibodies) determining the severity and/or course of COVID-19,
3) Analysis of barrier-destabilizing plasma mediators in COVID-19 and evaluation of barrier-stabilizing candidate substances,
4) Comparison of COVID-19 phenotypes, from uncomplicated pneumonia to ARDS, at the clinical and molecular level with CAP caused by other pathogens to improve clinical management, and
5) Analysis of variations of the SARS-CoV-2 genome and their association with specific clinical courses of COVID-19.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?


end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

Psydonomized clinical data and biomaterials that are collected within the framework of the PROVID-PROGRESS cohort are made available to the PROVID consortium for research purposes.
The results of the study are incorporated into joint publications.

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00023277
  •   2020/11/09
  •   [---]*
  •   yes
  •   Approved
  •   465-2009, Ethikkommission der Medizinischen Hochschule Hannover
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   DRKS00022871  (Teilstudie )
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   U07.1 -  Emergency use of U07.1
  •   J12 -  Viral pneumonia, not elsewhere classified
  •   J13 -  Pneumonia due to Streptococcus pneumoniae
  •   J14 -  Pneumonia due to Haemophilus influenzae
  •   J15 -  Bacterial pneumonia, not elsewhere classified
  •   J16 -  Pneumonia due to other infectious organisms, not elsewhere classified
  •   J17 -  Pneumonia in diseases classified elsewhere
  •   J18 -  Pneumonia, organism unspecified
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   The PROVID-PROGRESS study is being carried out as a prospective, longitudinal, multicenter observational study (case cohort study) with material reservation for genomic, transcriptomic and proteomic analyzes on adult patients with COVID-19.

    After study inclusion, comprehensive baseline documentation of anamnestic, clinical and laboratory data is collected on the same day if possible. In addition, all parameters are collected that may be necessary to assess the severity of a COVID-19 disease (e.g. SOFA, PSI, C (U) RB-65, ATS minor criteria). Furthermore, data is collected which, according to the current state of knowledge, may be suitable for an assessment of the prognosis of the COVID-19 disease. In particular, questions are asked about known infection risks (living environment of the patient, lifestyle, previous illnesses, immune competence), the history of symptoms and tests relating to COVID-19, preexisting medication, the familial risk of infection as well as ethnicity.
    On the day of inclusion (day 0) and on study visit days 1-6 and 13 - or for discharge if this occurs before day 6 or day 13 after inclusion - routine laboratory values, score-relevant data, concomitant medication and microbiological findings are documented.
    On discharge of the patient, additional information about his whereabouts is collected. If the patient dies, the date and cause of death are documented.
    On days 28, 180 and 360 after inclusion in the study, a follow-up survey takes place with particular attention to the living conditions and quality of life of the patient (EuroQol health questionnaire EQ-5D-3L), to health-related events such as stroke or heart attack and to the vital status. If the patient cannot be reached for the follow-up questionnaires, the including study center will attempt to determine the current contact details or vital status from relatives, the family doctor or, if necessary, from data from the residents' registration offices or other state registers, provided that consent is given.

    On study visit days 0, 1-3, 6 and 13, 4 blood samples each (P100 EDTA plasma, citrate plasma, serum and PAXgene RNA) are taken. A DNA sample (EDTA whole blood) is taken once and at any time.
    A nasopharynx swab is obtained on days 0, 3 and 6. If possible, sputum is obtained for inclusion and on visit day 6.
end of 1:N-Block interventions
start of 1:1-Block design


  •   Non-interventional
  •   Observational study
  •   Other
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Prognosis
  •   Other
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Severe course of disease (Necessity of treatment on intensive care unit or death).

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Length of hospitalization
length of ICU treatment
length of mechanical ventilation
organ involvement (complications)
long-term effects
changes in quality of life

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
  •   Austria
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2021/01/20
  •   200
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Positive detection of SARS-CoV-2-virus, Informed consent signed

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Patient participation in PROVID-CAPNETZ, PROVID-PROGRESS or PROVID-CAPSyS at an earlier time, simultaneous participation in PROVID-CAPNETZ, pregnancy, breast feeding period, active tuberculosis

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Charité – Universitätsmedizin Berlin, Med. Klinik m. S. Infektiologie und Pneumologie, und Arbeitsbereich Pulmonale Inflammation
    • Mr.  Prof. Dr. med.  Martin  Witzenrath 
    • Charitéplatz 1
    • 10117  Berlin
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover
    • 30625  Hannover
    • Germany
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Universität LeipzigInstitut für Medizinische Informatik, Statistik und Epidemiologie
    • Mr.  Prof. Dr. rer. nat.  Markus  Scholz 
    • Härtelstr. 16-18
    • 04107  Leipzig
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Charité - Universitätsmedizin BerlinMedizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie
    • Ms.  Dr. med.  Agata  Mikolajewska 
    • Campus Virchow-Klinikum, Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • BMBF/DLR-Projektträger
    • Heinrich-Konen-Str. 1
    • 53227  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up continuing
  •   [---]*
  •   [---]*
  •   [---]*
  •   86
  •   94
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.